July 30, 2019

Saqib Islam
Chief Executive Officer
SpringWorks Therapeutics, Inc.
100 Washington Blvd
Stamford, CT 06902

       Re: SpringWorks Therapeutics, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted July 22, 2019
           CIK No. 0001773427

Dear Mr. Islam:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus Summary
Overview, page 1

1.     We note your response to our prior comment 1. Please revise your
disclosure to
       summarize the information you provided in your response as it relates to
the timeline of
       the DeFi trial.
Our portfolio, page 2

2.     We note your response to our prior comment 2. Please revise your
disclosure to clarify,
       consistent with your response, that you have not yet determined the
international markets
       in which you will seek marketing approval.
 Saqib Islam
SpringWorks Therapeutics, Inc.
July 30, 2019
Page 2
3.    Please revise your pipeline table to indicate the progress of each of
your product
      candidates in a manner that is consistent with the disclosure elsewhere
in the prospectus.
      We note, for example, the table indicates that a number of candidates are
approximately
      halfway through a particular phase when the disclosure regarding those
candidates
      indicates they have not yet commenced or have recently commenced that
particular phase.
Business
Phase 2 clinical trial (WI180798), page 116

4.    We note your response to our prior comment 6 and your revised disclosure.
Please
      revise to state clearly why patient #14 "was not evaluable for response
per this trial
      protocol."
        You may contact Christine Torney at (202) 551-3652 or Angela Connell at
(202) 551-
3426 if you have questions regarding comments on the financial statements and
related
matters. Please contact Tonya Aldave at (202) 551-3601 or Justin Dobbie at
(202) 551-3469
with any other questions.



                                                             Sincerely,
FirstName LastNameSaqib Islam
                                                             Division of
Corporation Finance
Comapany NameSpringWorks Therapeutics, Inc.
                                                             Office of
Healthcare & Insurance
July 30, 2019 Page 2
cc:       Kingsley Taft, Esq.
FirstName LastName